Research, editing : Gan Yung Chyan, KUCINTA SETIA
News on disease control, CCP
News (1) to (2) / Reporter : Lv Xinwen / Source : The Paper via China Science News / https://news.sciencenet.cn/htmlnews/2023/2/494286.shtm
News (1)
National Health Commission: Further improve the biosafety management of the SARS-CoV-2 laboratory
Image : Web Screenshot
Recently, the General Office of the National Health Commission has issued the "Notice on Further Improving the Biosafety Management of Novel Coronavirus Laboratories", which has been forwarded and implemented by health departments in many places across the country.
According to the news from the website of the Jinzhong City Health Commission of Shanxi Province on 15 February 2023, and according to previous news from the websites of the Anhui Provincial Health Commission, Beijing Municipal Health Commission, and Taiyuan Municipal Health Commission, the General Office of the National Health Commission announced on 17 January 2023 the "Notice on Further Improving the Biosafety Management of Novel Coronavirus Laboratories" stated that with the optimization and adjustment of policies for the prevention and control of SARS-CoV-2 infection epidemics, the biosafety of pathogenic microorganism laboratories is facing new situations and tasks.
The General Office of the National Health Commission stated to the health committees of provinces, autonomous regions, municipalities directly under the Central Government and Xinjiang Production and Construction Corps that in order to ensure laboratory biosafety and prevent biosafety risks, according to the "Biosafety Law of the People's Republic of China" and "Pathogenic Microorganism Laboratory Biology Safety Management Regulations and other relevant regulations to further improve the biosafety management of the new coronavirus laboratory.
About the management of SARS-CoV-2 experiment activities
SARS-CoV-2 continues to be managed according to the second type of pathogenic microorganisms. SARS-CoV-2 cultivation and animal infection experiments should be carried out in biosafety level 3 and above laboratories; the operation of uncultivated infectious materials and inactivated materials should be carried out in biosafety level 2 and above laboratories. The operation of inactivated or fixed human and animal tissue specimens should be carried out in third-level laboratories and above; the operation of non-infectious materials can be carried out in biosafety level-one laboratories. Experimental activities carried out in third-level and above laboratories shall be approved according to law before carrying out. Laboratories should select appropriate personal protective equipment based on risk assessment results.
About SARS-CoV-2 sample transportation management
The SARS-CoV-2 strain or uncultivated potentially infectious biological material samples belong to Class A infectious substances, and the corresponding UN number is UN2814. The packaging should meet the PI620 classification packaging requirements of the World Health Organization's "Guidelines for the Regulations on the Transport of Infectious Substances". It should be approved by the health administrative department above the provincial level. Environmental samples are managed in accordance with Class B infectious substances, and the corresponding UN number is UN3373, and the packaging should meet the PI650 classification packaging requirements of the World Health Organization's "Guidelines for the Regulations and Regulations on the Transport of Infectious Substances". The transportation of infectious substances shall comply with the regulations of the corresponding transportation authorities on the transportation of dangerous goods. Inactivated samples are managed as non-infectious materials.
About SARS-CoV-2 strains and sample management
SARS-CoV-2 strains and infectious samples should be centrally managed by dedicated personnel, accurately record the source, type, and quantity of strains and infectious samples, establish a ledger for registration and numbering, and take effective measures to ensure safety. All laboratories and their establishment units should especially strengthen the management of past epidemic strains and infectious samples of the new coronavirus and their experimental activities. After the experimental activities are over, the laboratory should send the virus strains to the preservation institution for preservation or destroy them on the spot within 6 months; the infectious samples should be destroyed or inactivated on the spot in principle, and the non-inactivated samples that really need to be preserved should be timely send it to an institution that meets the preservation conditions for preservation, or send it to a preservation institution for preservation. New mutant strains isolated by the laboratory should be sent to the preservation institution for preservation within 90 days.
News (2)
Strengthen laboratory biosafety supervision
The establishment unit of the laboratory must effectively implement the main responsibility, strengthen the management of laboratory biosafety, establish and improve the management system, strengthen personnel training, operate in strict accordance with laws, regulations and relevant standards, carry out regular self-examination, and timely investigate and eliminate hidden risks. Health and health administrative departments at all levels must perform regulatory duties in accordance with the law, improve laboratory biosafety supervision capabilities, and conscientiously do a good job in laboratory-related licensing and filing in accordance with the principles of localization and classification, strengthen laboratory supervision and inspection, and supervise laboratories. Its establishment unit regulates management, and violations of laws and regulations are found to be strictly investigated and dealt with in accordance with the law.
No comments:
Post a Comment